A phase II trial of patients with newly diagnosed, inoperable, gastrointestinal stromal tumour (GIST) is using existing technologies to personalise treatment, an Australian medical oncologist says.
Part of the Australian Gastro-Intestinal Trial Group, the REGISTER trial is designed to evaluate imantinib dose escalation followed by nilotinib after progressive disease, according to stratification into exon 11 and non-exon 11/WT mutational status.
The functional response to therapy, as determined by FDG-PET, will be correlated with pharmacokinetics after administration.
The trial’s principal investigator Dr. Jayesh Desai from Royal Melbourne Hospital, said that although GIST is rare it is also unique as the majority of these tumours are driven by mutations in the tumour cell signalling KIT.
“The thing about GIST is that even...
This site is intended for Registered Medical Practitioners.
To make the most of Gastroenterology Update, you need to be logged in.